53 results
8-K
EX-99.2
TCRX
Tscan Therapeutics Inc
16 Apr 24
TScan Therapeutics Provides Clinical Pipeline Update and Highlights Near-Term Priorities
4:16pm
study due to relapse or death 15 Data cutoff April 12, 2024 CONFIDENTIAL
Donor chimerism serves as an early surrogate of efficacy Post-transplant … -negative MDS Control-3 RELAPSE X AML Control-4 Clinical intervention # AML Control-5 Death X AML Control-6 Ongoing follow-up Control-7 AML X Control
8-K
438zv87kz8kjvlm
7 Dec 23
TScan Therapeutics Appoints R. Keith Woods to its Board of Directors, Bringing Expertise in Commercialization and Global Operations
7:15am
DEFA14A
gagqtt6xua8egvm
2 Jun 23
Additional proxy soliciting materials
4:05pm
8-K
xjplng 69hmw0iwvvq1d
31 May 23
TScan Therapeutics Appoints Gavin MacBeath, Ph.D. as Chief Executive Officer and as a Member of the Board of Directors
8:00am
8-K
af8e a5qlw8
10 Apr 23
TScan Therapeutics Announces Appointment of Barbara Klencke, M.D., to its Board of Directors
7:45am
DEF 14A
5rv6uux
21 Apr 22
Definitive proxy
8:00am